GC Biopharma Expands Asian Presence with Thai Red Cross Partnership for Plasma-Derived Therapeutics
Key Insights
GC Biopharma (search) signed a memorandum of understanding with the Thai Red Cross Society (search) to strengthen workforce training for plasma-derived medicinal products (search) production.
The partnership builds on a decade-long relationship that began in 2015 when GC Biopharma (search) helped establish Thailand's plasma fractionation facility.
The collaboration will include technology transfer programs and potential joint projects for plasma by-product processing technologies.
GC Biopharma (search), a South Korean biopharmaceutical company, has formalized a strategic partnership with the Thai Red Cross Society (search) (TRCS) through a memorandum of understanding aimed at strengthening collaboration on plasma-derived therapeutics. The agreement, announced on August 18, 2025, deepens a relationship that began in 2015 when GC Biopharma supported TRCS in establishing a plasma fractionation facility in Thailand.
Technology Transfer and Workforce Development
Under the terms of the MOU, both organizations will jointly develop and operate on-site training and exchange programs for local production personnel. These initiatives are designed to transfer GC Biopharma (search)'s advanced manufacturing technologies and expertise to support the development of local capabilities in Thailand's plasma-derived therapeutics sector.
"This MOU is a significant step in broadening the reach of GC Biopharma (search)'s advanced technology and production standards across Asia," said Hyoungjun Park, Vice President of GC Biopharma. "Through our collaboration with the TRCS, we aim to achieve mutual growth while contributing to the public good."
The partnership extends beyond immediate training programs, with both parties committed to identifying and expanding collaborative opportunities that align with their respective strengths. The scope of cooperation will gradually broaden to include potential joint projects such as the transfer of new processing technologies for plasma by-products and other strategic initiatives.
Strengthening Thailand's Pharmaceutical Infrastructure
Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre at TRCS, emphasized the critical importance of the collaboration for Thailand's healthcare security. "Enhancing our personnel's capabilities through specialized training and direct knowledge transfer from GC Biopharma (search) is essential to maintaining the quality, safety, and continuity of plasma-derived medicinal products (search) production in Thailand," he stated.
The partnership represents a vital step for technology transfer and plays an important role in strengthening Thailand's pharmaceutical and public health security, according to Chaiwanichsiri. The collaboration supports both human resource development and the broader goal of building domestic capabilities in plasma-derived therapeutics production.
Strategic Expansion in Southeast Asia
This partnership aligns with GC Biopharma (search)'s broader strategy to expand its global plasma-derived therapeutics business, particularly in Southeast Asia where domestic fractionation capabilities remain limited. The company successfully entered the U.S. immunoglobulin market in 2024 with its Alyglo (search)® (intravenous immunoglobulin G (search)) product and is now actively building partnerships throughout Southeast Asia.
GC Biopharma (search), formerly known as Green Cross Corporation, brings over half a century of experience in the development and manufacturing of plasma derivatives and vaccines to this collaboration. The company continues to drive innovation by leveraging its core R&D capabilities in protein engineering, mRNAs, and lipid nanoparticle drug delivery platforms to develop therapeutics for rare diseases and immunology and inflammation applications.